Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15,264 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Inflammatory cytokine profiles during Cyclosporin treatment for immunoglobulin-resistant Kawasaki disease.
Hamada H, Suzuki H, Abe J, Suzuki Y, Suenaga T, Takeuchi T, Yoshikawa N, Shibuta S, Miyawaki M, Oishi K, Yamaga H, Aoyagi N, Iwahashi S, Miyashita R, Honda T, Onouchi Y, Terai M, Hata A. Hamada H, et al. Among authors: suzuki h, suzuki y. Cytokine. 2012 Dec;60(3):681-5. doi: 10.1016/j.cyto.2012.08.006. Epub 2012 Sep 1. Cytokine. 2012. PMID: 22944461 Clinical Trial.
Cyclosporin A treatment for Kawasaki disease refractory to initial and additional intravenous immunoglobulin.
Suzuki H, Terai M, Hamada H, Honda T, Suenaga T, Takeuchi T, Yoshikawa N, Shibuta S, Miyawaki M, Oishi K, Yamaga H, Aoyagi N, Iwahashi S, Miyashita R, Onouchi Y, Sasago K, Suzuki Y, Hata A. Suzuki H, et al. Among authors: suzuki y. Pediatr Infect Dis J. 2011 Oct;30(10):871-6. doi: 10.1097/INF.0b013e318220c3cf. Pediatr Infect Dis J. 2011. PMID: 21587094
Study protocol for a phase III multicentre, randomised, open-label, blinded-end point trial to evaluate the efficacy and safety of immunoglobulin plus cyclosporin A in patients with severe Kawasaki disease (KAICA Trial).
Aoyagi R, Hamada H, Sato Y, Suzuki H, Onouchi Y, Ebata R, Nagashima K, Terauchi M, Terai M, Hanaoka H, Hata A; KAICA Trial Investigators. Aoyagi R, et al. Among authors: suzuki h. BMJ Open. 2015 Dec 1;5(12):e009562. doi: 10.1136/bmjopen-2015-009562. BMJ Open. 2015. PMID: 26628527 Free PMC article. Clinical Trial.
ITPKC and CASP3 polymorphisms and risks for IVIG unresponsiveness and coronary artery lesion formation in Kawasaki disease.
Onouchi Y, Suzuki Y, Suzuki H, Terai M, Yasukawa K, Hamada H, Suenaga T, Honda T, Honda A, Kobayashi H, Takeuchi T, Yoshikawa N, Sato J, Shibuta S, Miyawaki M, Oishi K, Yamaga H, Aoyagi N, Iwahashi S, Miyashita R, Murata Y, Ebata R, Higashi K, Ozaki K, Sasago K, Tanaka T, Hata A. Onouchi Y, et al. Among authors: suzuki h, suzuki y. Pharmacogenomics J. 2013 Feb;13(1):52-9. doi: 10.1038/tpj.2011.45. Epub 2011 Oct 11. Pharmacogenomics J. 2013. PMID: 21987091
15,264 results
You have reached the last available page of results. Please see the User Guide for more information.